Biological agents: A trial performed with anti-IL-5 monoclonal antibody showed a significant reduction of eosinophils in the esophageal tissue and may play an important role in the future therapy of EoE.[34]. This evidence concerns the gene IL5 and eosinophilic esophagitis.